Recall Register

Food, drugs, devices › Amgen, Inc.

Drug recall: Prolia (denosumab) Injection, 60 mg/mL, 1 x 60 mg Single Use Prefilled Syringe per carton, Rx only, Manufactured by: Amg

FDA enforcement event 66318 · Class II · initiated 17 Sep 2013 · status Terminated · terminated 2 Jun 2014

DrugVoluntary: Firm initiated1 product recordThousand Oaks, CA

FDA enforcement event 66318 is a drug recall by Amgen, Inc. of Thousand Oaks, CA, initiated 17 Sep 2013 and classified Class II, with 1 product record.

FDA defines Class II as a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote. 56% of the 370 drug enforcement events initiated in 2013 carry the same class.

Status: Terminated, terminated 2 Jun 2014. Initiation: voluntary: firm initiated. Amgen, Inc. has 7 enforcement events on this register, with a median of 1 product record per event.

Recall classification reflects the relative degree of health hazard. Text in quotation marks is FDA's. openFDA export dated 28 Sep 2026.

Recalling firm

Amgen, Inc., Thousand Oaks, CA.

Reason for recall

"Presence of Particulate Matter: Visible cellulose fibers were observed in a small number of prefilled syringes during a routine quality examination."

Distribution

"Nationwide and Puerto Rico, Canada, Mexico, and clinical distribution in Europe."

Product records

Recall numberProductQuantityClassStatusReport date
D-66318-001Prolia (denosumab) Injection, 60 mg/mL, 1 x 60 mg Single Use Prefilled Syringe per carton, Rx only, Manufactured by: Amgen Manufacturing Ltd., a subsidiary of Amgen Inc., Thousand Oaks, CA 91320-1799,NDC 55513-710-01, UPC 3 55513 71001 5.4,163 prefilled syringesClass IITerminated13 Nov 2013

Context

56%of 2013 drug events are Class II370 events that year
1product record in this eventfirm median: 1
7events on this register for the firm

Other enforcement events for Amgen, Inc.

InitiatedProduct (first record)TypeClassRecords
4 Jun 2026Corlanor (ivabradine) tablets, 5 mg, packaged in a) 14 tablets bottles (NDC 55513-800-99), and b) 60 tablet bottles (NDCDrugClass II5
27 Feb 2025Neupogen (filgrastim) For Injection, 300mcg/1 mL, 1 mL Single Dose Vials, Rx Only, For Subcutaneous or Intravenous Use ODrugClass II2
2 May 2022MVASI (bevacizumab-awwb), Injection, For Intravenous Infusion After Dilution, 100 mg/4 ml, Single dose vial, Rx only, MaDrugClass II1
13 Sep 2017Procrit (epoetin alfa), 10,000 units/mL, packaged in a) box of 6 single use 1 mL vials (NDC 59676-310-01), b) box of 25 DrugClass II1
4 Aug 2017Procrit Epoetin Alfa 40,000 units/mL single use vial For Intravenouse or Subcutaneous Use Only, Rx only, Manufactured byDrugClass II1
15 Dec 2016AMGEN Kyprolis (carfilzomib) for injection, 30 mg per vial, Discard unused portion, For Intravenous Administration Only,DrugClass II1

All 7 events for Amgen, Inc.

Questions and answers

Why was this drug recalled?

FDA's record gives the reason for recall as: "Presence of Particulate Matter: Visible cellulose fibers were observed in a small number of prefilled syringes during a routine quality examination."

What does Class II mean?

FDA classifies recalls by relative degree of health hazard. Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote.

Where was the product distributed?

FDA's distribution pattern field reads: "Nationwide and Puerto Rico, Canada, Mexico, and clinical distribution in Europe."

Is the recall still ongoing?

FDA lists the status as Terminated; the termination date is 2 Jun 2014. "Terminated" means FDA has determined that all reasonable efforts to remove or correct the product have been made.

Where does this data come from?

openFDA enforcement reports (food, drug and device), CC0, export dated 28 Sep 2026. Text in quotation marks is FDA's. The FDA enforcement report linked above is authoritative.

Provenance

Source: openFDA drug enforcement reports (CC0), export dated 28 Sep 2026; records grouped by FDA event number. The class shown for the event is the most severe class among its records. Errors in processing are corrected at the next build; see corrections.